Eton Pharmaceuticals Files 8-K
Ticker: ETON · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1710340
Sentiment: neutral
Topics: 8-K, filing, regulatory
TL;DR
Eton Pharma filed an 8-K, likely with important company updates.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on February 7, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about the nature of these events or financial statements within the provided text.
Why It Matters
This filing indicates that Eton Pharmaceuticals has made a regulatory submission to the SEC, which could contain significant updates about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard procedural document without immediate disclosed financial impact or significant operational changes.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- 001-38738 (company) — SEC File Number
- 37-1858472 (company) — I.R.S. Employer Identification Number
- 21925 W. Field Parkway , Suite 235 Deer Park , Illinois 60010 -7208 (company) — Principal executive offices address
- ( 847 ) 787-7361 (company) — Registrant's telephone number
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates "Other Events" and "Financial Statements and Exhibits" as item information, but the specific details of these events are not provided in the excerpt.
When was this 8-K report filed?
The report was filed on February 7, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Eton Pharmaceuticals, Inc.
In which state was Eton Pharmaceuticals, Inc. incorporated?
Eton Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address for Eton Pharmaceuticals, Inc.?
The principal executive office address is 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
Filing Stats: 475 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-02-07 07:15:34
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20250203_8k.htm (8-K) — 26KB
- ex_774026.htm (EX-99.1) — 11KB
- 0001437749-25-003070.txt ( ) — 173KB
- eton-20250207.xsd (EX-101.SCH) — 3KB
- eton-20250207_def.xml (EX-101.DEF) — 12KB
- eton-20250207_lab.xml (EX-101.LAB) — 15KB
- eton-20250207_pre.xml (EX-101.PRE) — 12KB
- eton20250203_8k_htm.xml (XML) — 3KB
01: Other Events
Item 8.01: Other Events On February 7, 2025, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent No. 12,214,010, covering its ET-600 product candidate's proprietary formulation of desmopressin oral solution. The patent expires in 2044 and is expected to be listed in the FDA Orange Book upon the product's approval. The Company has an additional patent application related to the product under review with the USPTO. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated February 7, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 7, 2025 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4